IP Library › Granted Patent US 11,773,119
Granted Patent B2
US 11,773,119 · App. 16/998,426 · Granted Oct 3, 2023

Prodrugs of pyridone amides useful as modulators of sodium channels

Inventors: Corey Anderson (San Diego, CA); Sara Sabina Hadida Ruah (LaJolla, CA); Julian Marian Charles Golec (Abingdon, GB); Beili Zhang (San Diego, CA); Benjamin Joseph Littler (Carlsbad, CA); Ali Keshavarz-Shokri (San Diego, CA); Tim Edward Alcacio (San Diego, CA); Daniel T. Belmont (Grafton, MA)
Assignee: VERTEX PHARMACEUTICALS INCORPORATED
C07F9/58A61K31/675A61K45/06C07F9/576C07F9/59
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,773,119
App. No.
16/998,426
Granted
Oct 3, 2023
Kind
B2
Abstract

The invention relates to prodrug compounds of formula I: wherein R 2 , R 3 , R 5 , R 7 and X are as defined herein. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain. The compounds of formula I possess advantageous solubility and physicochemical properties.

Claims (74)

1. A process for preparing a compound of formula I:

wherein, independently for each occurrence:

R 2 and R 3 are independently hydrogen, halogen, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen;

R 5 is hydrogen, halogen, OH, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—;

R 7 is hydrogen, halogen, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—; and

X is —PO(OH) 2 , —PO(OH)O − M + , —PO(O − ) 2 ·2M + , or —PO(O − ) 2 D 2+ ; M + is a pharmaceutically acceptable monovalent cation; and D 2+ is a pharmaceutically acceptable divalent cation;

provided that R 2 , R 3 , R 5 , and R 7 are not simultaneously hydrogen;

comprising:

transforming a compound of formula B:

to a compound of formula I, wherein X is P(O)(OH) 2 ; and

optionally, treating the compound of formula I, wherein X is P(O)(OH) 2 , with M + OH − or D 2+ (OH − ) 2 to afford the compound of formula I, wherein X is P(O)(OH)(O − )—M + , P(O)(O − ) 2 ·D 2+ , or P(O)(O − ) 2 ·D 2+ .

2. The process according to claim 1 , further comprising treating a compound of formula A:

with chloromethyl chloroformate to afford the compound of formula B.

3. The process according to claim 1 , wherein said transforming the compound of formula B to the compound of formula I, wherein X is P(O)(OH) 2 , comprises treating the compound of formula B with K(PG 1 ) 2 PO 4 to afford a compound of formula C:

and

deprotecting the compound of formula C to afford the compound of formula I, wherein X is P(O)(OH) 2 .

4. The process according to claim 2 , wherein said transforming the compound of formula B to the compound of formula I, wherein X is P(O)(OH) 2 , comprises treating the compound of formula B with K(PG 1 ) 2 PO 4 to afford a compound of formula C:

and

deprotecting the compound of formula C to afford the compound of formula I, wherein X is P(O)(OH) 2 .

5. The process according to claim 3 , wherein PG 1 is tert-butyl.

6. The process according to claim 4 , wherein PG 1 is tert-butyl.

7. The process according to claim 3 , wherein:

R 2 is H;

R 3 is CF 3 ;

R 5 is CH 3 ;

R 7 is F; and

X is —PO(OH) 2 .

8. The process according to claim 3 , wherein:

R 2 is H;

R 3 is CF 2 CF 3 ;

R 5 is OCH 3 ;

R 7 is F; and

X is —PO(OH) 2 .

9. The process according to claim 3 , wherein:

R 2 is H;

R 3 is Cl;

R 5 is CH 3 ;

R 7 is F; and

X is —PO(OH) 2 .

10. The process according to claim 3 , wherein:

R 2 is CF 3 ;

R 3 is H;

R 5 is CH 3 ;

R 7 is F; and

X is —PO(OH) 2 .

11. The process according to claim 3 , wherein:

R 2 is CF 3 ;

R 3 is H;

R 5 is H;

R 7 is F; and

X is —PO(OH) 2 .

12. The process according to claim 3 , wherein:

R 2 is Cl;

R 3 is Cl;

R 5 is OCH 3 ;

R 7 is F; and

X is —PO(OH) 2 .

13. A compound of formula B:

wherein, independently for each occurrence:

R 2 and R 3 are independently hydrogen, halogen, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen;

R 5 is hydrogen, halogen, OH, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—; and

R 7 is hydrogen, halogen, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—.

14. The compound according to claim 13 , wherein the compound is selected from the group consisting of:

15. The compound according to claim 13 , wherein the compound is:

16. The compound according to claim 13 , wherein the compound is:

17. A compound of formula C:

wherein, independently for each occurrence:

R 2 and R 3 are independently hydrogen, halogen, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen;

R 5 is hydrogen, halogen, OH, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—;

R 7 is hydrogen, halogen, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen and wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—; and

PG 1 is a protecting group.

18. The compound according to claim 17 , wherein the compound is selected from the group consisting of:

19. The compound according to claim 17 , wherein the compound is:

20. The compound according to claim 17 , wherein the compound is:

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: ANDERSON, COREY; ZHANG, BEILI; LITTLER, BENJAMIN JOSEPH; KESHAVARZ-SHOKRI, ALI; ALCACIO, TIM EDWARD; HADIDA RUAH, SARA SABINA
To: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC.
Reel/Frame 053559/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 053559/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: GOLEC, JULIAN MARIAN CHARLES
To: VERTEX PHARMACEUTICALS (EUROPE) LIMITED
Reel/Frame 053559/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: VERTEX PHARMACEUTICALS (EUROPE) LIMITED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 053559/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: BELMONT, DANIEL T.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 053560/0001 →
Continuity (7)
Continuation 16283904 · Feb 25, 2019
Continuation 15791982 · Oct 24, 2017
Continuation 15260778 · Sep 9, 2016
Continuation 14858635 · Sep 18, 2015
Continuation 14568391 · Dec 12, 2014
Provisional Application 61915937 · Dec 13, 2013
Related Publication 20200377535A1 · Dec 3, 2020
Cited By (3)
US 12,258,333 US 12,503,439 US 12,662,470